Company Overview and News

1
PSBank looks to raise P8 billion via stock rights offer in Q1 2019

2018-10-16 bworldonline - 1
PHILIPPINE SAVINGS Bank (PSBank) is set to raise approximately P8 billion through a stock rights offer (SRO) next quarter to support its growth.
RZLLY RCB PSB

 
Metrobank raises P8.68 billion

2018-10-04 bworldonline
METROPOLITAN Bank & Trust Co. (Metrobank) has raised P8.68 billion from the first tranche of its P25-billion long-term negotiable certificates of deposit (LTNCD) program meant to diversify its funding sources.
CHIB RZLLY RCB CKGOY PSB

 
Metrobank offers LTNCDs

2018-09-17 bworldonline
METROPOLITAN BANK & Trust Co. (Metrobank) started offering long-term negotiable certificates of time deposit (LTNCD) on Monday to diversify its funding sources.
CHIB RZLLY RCB CKGOY PSB

 
PSBank net jumped 14.7% in first 6 months

2018-08-09 business.inquirer.net
Metrobank group’s thrift banking arm, Philippine Savings Bank, grew its net profit in the first semester by 14.7 percent year-on-year to P1.35 billion on higher earnings from lending and fee-based businesses.
PSB

 
PSBank net profit climbs in first half

2018-08-09 bworldonline
Philippine Savings Bank (PSBank) reported higher net income in the the first half of the year on the back of strong net interest income and service fees.
PSB

 
PSBank speeds up approval of home loan applications

2018-08-07 bworldonline
Philippine Savings Bank (PSBank) sets its decision on home loan applications to one day for the purchase of condominium units and properties.
PSB

2
PSBank starts offer of P3-billion LTNCDs

2018-07-25 bworldonline - 2
PHILIPPINE SAVINGS Bank (PSBank) has started its offer of long-term negotiable certificates of deposit (LTNCD), which will be used to expand its consumer banking segment.
CHIB CKGOY PSB

1
PSBank starts LTNCD offering

2018-07-24 bworldonline - 1
Philippine Savings Bank (PSBank) has started its offer of long-term negotiable certificates of deposit (LTNCD) which will be used to expand its consumer banking segment.
PSB

 
PSBank seeks to raise P15B

2018-07-17 business.inquirer.net
Philippine Savings Bank, the thrift bank arm of the Metrobank group, plans to raise up to P15 billion from an offering of high-yielding deposits.
PSKXF PHSXY PSE PSB

 
PSBank gets BSP nod for LTNCDs

2018-07-17 bworldonline
PHILIPPINE SAVINGS Bank (PSBank) has received regulatory approval to raise up to P15 billion in long-term negotiable certificates of deposit (LTNCD) to expand its consumer banking segment.
CHIB CKGOY PSB

 
PSBank secures BSP approval for P15-billion LTNCD issuance

2018-07-17 bworldonline
Philippine Savings Bank (PSBank) has received the central bank’s approval to raise funds through long-term negotiable certificates of deposit (LTNCD) to expand its consumer banking segment.
PSB

1
PSBank sees increased usage of cardless withdrawal feature

2018-06-08 bworldonline
Philippine Savings Bank (PSBank) saw pickup in the usage of its cardless withdrawal feature in its automated teller machines as it proves to be “relevant” to the needs of its client base.
PSB

1
PSBank looks to use proceeds of planned LTNCD sale to expand consumer segment

2018-06-05 bworldonline
PHILIPPINE SAVINGS Bank (PSBank) said it will raise funds through long-term negotiable certificates of time deposit (LTNCD) to expand its consumer banking segment.
PSB

9
Can consumers keep on availing of car loans amid TRAIN?

2018-05-27 bworldonline
BANKS HAVE BEEN lending out more readily to consumers, offering promos and flexible payment schemes to entice first-time buyers or even those wanting to buy a second car. This ease of credit, coupled with households’ increasing disposable incomes, have led to the increasing share of car loans into the banks’ loan portfolios over the years.
UBNC SYBJF RZLLY RCB SECB PSB

12
PBCom to offer LTNCDs

2018-05-25 bworldonline - 1
PHILIPPINE Bank of Communications (PBCom) is set to raise up to P5 billion by selling peso-denominated long-term negotiable certificates of time deposit (LTNCD).
BDOUF BDO CHIB BDOUY SYBJF SECB CKGOY PSB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:PSB / Philippine Savings Bank on message board site Silicon Investor.

PSB Bancorp (PSBI) PSB Bancorp (PSBI) PSB Bancorp (PSBI)